Mary Crowley Cancer Research

Summary

Mary Crowley Cancer Research is a medical facility located in Dallas, Texas. This center is recognized for care of Solid Tumors, Cancer, Lung Cancer, Pancreatic Cancer, Breast Cancer and other specialties. Mary Crowley Cancer Research is involved with conducting 290 clinical trials across 217 conditions. There are 6 research doctors associated with this hospital, such as Minal Barve, MD, James Strauss, Douglas Orr, MD, and Reva Schneider.

Top PIs

Clinical Trials running at Mary Crowley Cancer Research

Solid Tumors

Breast Cancer

Lung Cancer

Cancer

Pancreatic Cancer

Ovarian Cancer

Colorectal Cancer

Endometrial Cancer

Prostate Cancer

Bladder Cancer

Dabrafenib + Trametinib Access

for Cancer

This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.

Recruiting

3 awards

Phase 4

2 criteria

T3011 + Pembrolizumab

for Solid Cancers

This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.

Recruiting

2 awards

Phase 1 & 2

14 criteria

ABSK061

for Solid Tumors

This is an open-label phase 1 study with expansion. The study will start with a dose escalation of single-agent ABSK061 administered in repeated 28-day cycles in patients with advanced solid tumors to evaluate safety and tolerability. The expansion part will investigate oral ABSK061 at the recommended dose for expansion (RDE) to further evaluate safety and tolerability among selected tumor types. Preliminary antitumor activity will also be assessed.

Recruiting

1 award

Phase 1